These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
325 related articles for article (PubMed ID: 21729319)
21. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Ozkan EE Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884 [TBL] [Abstract][Full Text] [Related]
22. Defining the pathway to insulin-like growth factor system targeting in cancer. Rosenzweig SA; Atreya HS Biochem Pharmacol; 2010 Oct; 80(8):1115-24. PubMed ID: 20599789 [TBL] [Abstract][Full Text] [Related]
23. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. Tovar V; Cornella H; Moeini A; Vidal S; Hoshida Y; Sia D; Peix J; Cabellos L; Alsinet C; Torrecilla S; Martinez-Quetglas I; Lozano JJ; Desbois-Mouthon C; Solé M; Domingo-Domenech J; Villanueva A; Llovet JM Gut; 2017 Mar; 66(3):530-540. PubMed ID: 26658144 [TBL] [Abstract][Full Text] [Related]
24. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273 [TBL] [Abstract][Full Text] [Related]
25. Can we unlock the potential of IGF-1R inhibition in cancer therapy? King H; Aleksic T; Haluska P; Macaulay VM Cancer Treat Rev; 2014 Oct; 40(9):1096-105. PubMed ID: 25123819 [TBL] [Abstract][Full Text] [Related]
26. IGF-1R as an anti-cancer target--trials and tribulations. Chen HX; Sharon E Chin J Cancer; 2013 May; 32(5):242-52. PubMed ID: 23601239 [TBL] [Abstract][Full Text] [Related]
27. IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways. Cai W; Ma Y; Song L; Cao N; Gao J; Zhou S; Tang X BMC Cancer; 2023 Jan; 23(1):87. PubMed ID: 36698167 [TBL] [Abstract][Full Text] [Related]
28. The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer. Heidegger I; Massoner P; Sampson N; Klocker H Cancer Lett; 2015 Oct; 367(2):113-21. PubMed ID: 26231734 [TBL] [Abstract][Full Text] [Related]
29. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. Singh P; Alex JM; Bast F Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270 [TBL] [Abstract][Full Text] [Related]
30. Dual sphingosine kinase inhibitor SKI-II enhances sensitivity to 5-fluorouracil in hepatocellular carcinoma cells via suppression of osteopontin and FAK/IGF-1R signalling. Grbčić P; Tomljanović I; Klobučar M; Kraljević Pavelić S; Lučin K; Sedić M Biochem Biophys Res Commun; 2017 Jun; 487(4):782-788. PubMed ID: 28433634 [TBL] [Abstract][Full Text] [Related]
31. Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation. Bodzin AS; Wei Z; Hurtt R; Gu T; Doria C J Cell Physiol; 2012 Jul; 227(7):2947-52. PubMed ID: 21959795 [TBL] [Abstract][Full Text] [Related]
32. The regulation of proliferation and apoptosis in hepatocellular carcinoma via insulin-like growth factor 1 receptor. Xu G; Chu J; Shi Y; Huang L; Fu J Growth Horm IGF Res; 2022 Oct; 66():101499. PubMed ID: 36084573 [TBL] [Abstract][Full Text] [Related]
33. Insulin-Like Growth Factor 1 Receptor Drives Hepatocellular Carcinoma Growth and Invasion by Activating Stat3-Midkine-Stat3 Loop. Bie C; Chen Y; Tang H; Li Q; Zhong L; Peng X; Shi Y; Lin J; Lai J; Wu S; Tang S Dig Dis Sci; 2022 Feb; 67(2):569-584. PubMed ID: 33559791 [TBL] [Abstract][Full Text] [Related]
34. Benzylidene-indolinones are effective as multi-targeted kinase inhibitor therapeutics against hepatocellular carcinoma. Ho HK; Chua BT; Wong W; Lim KS; Teo V; Ong HT; Chen X; Zhang W; Hui KM; Go ML; Ullrich A Mol Oncol; 2014 Oct; 8(7):1266-77. PubMed ID: 24839937 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma. Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037 [TBL] [Abstract][Full Text] [Related]
36. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Dong J; Demarest SJ; Sereno A; Tamraz S; Langley E; Doern A; Snipas T; Perron K; Joseph I; Glaser SM; Ho SN; Reff ME; Hariharan K Mol Cancer Ther; 2010 Sep; 9(9):2593-604. PubMed ID: 20716637 [TBL] [Abstract][Full Text] [Related]
37. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors. Scartozzi M; Bianconi M; Maccaroni E; Giampieri R; Del Prete M; Berardi R; Cascinu S Discov Med; 2011 Feb; 11(57):144-53. PubMed ID: 21356169 [TBL] [Abstract][Full Text] [Related]
38. Targeting IGF-1R in the treatment of sarcomas: past, present and future. Kim SY; Wan X; Helman LJ Bull Cancer; 2009; 96(7):E52-60. PubMed ID: 19617179 [TBL] [Abstract][Full Text] [Related]
39. Targeted therapy of the insulin-like growth factor-1 receptor in cancer. Paz K; Hadari YR Comb Chem High Throughput Screen; 2008 Jan; 11(1):62-9. PubMed ID: 18220543 [TBL] [Abstract][Full Text] [Related]
40. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy. Hua H; Kong Q; Yin J; Zhang J; Jiang Y J Hematol Oncol; 2020 Jun; 13(1):64. PubMed ID: 32493414 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]